33 citations
,
October 2013 in “Journal of The American Academy of Dermatology” In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.
24 citations
,
April 2008 in “Fertility and sterility” In this study, pioglitazone treatment in insulin-resistant PCOS patients decreased relative 5alpha-reductase activity without significantly affecting cortisol levels or urinary cortisol excretion.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
9 citations
,
November 2018 in “Acta Clinica Belgica” This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.
January 2004 in “Data Archiving and Networked Services (DANS)” This study found that finasteride blocked the progesterone-induced increase in spike-wave discharges in rats, suggesting that this effect of progesterone is mediated by its metabolite allopregnanolone.
February 2024 in “Practical Diabetes” This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.
January 1994 in “Journal of Dermatological Treatment” This case report describes the effective use of spironolactone for hirsutism in a patient with porphyria cutanea tarda.
February 2025 in “Iranian journal of pharmaceutical research”
2 citations
,
September 2021 in “Human Psychopharmacology: Clinical and Experimental” This review discusses valproate-associated hair abnormalities, describing their common and benign nature, and outlines management strategies, though new clinical results are not provided.
June 2011 in “Pharmacopsychiatry” This correction clarifies the affiliations of researcher D. Piomelli in a case report on symptom improvement in a chronic psychotic patient treated with finasteride, without presenting new research findings.
5 citations
,
January 2017 in “Nevrologiâ, nejropsihiatriâ, psihosomatika” In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.
41 citations
,
February 2021 in “Cureus” In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” This study found that isoallopregnanolone reduced stress-induced tic-like behaviors and sensorimotor gating deficits in a mouse model of Tourette syndrome, suggesting potential therapeutic properties comparable to existing treatments like haloperidol and finasteride.
53 citations
,
October 2011 in “Psychoneuroendocrinology” Finasteride may help improve certain brain function issues linked to dopamine.
November 2007 in “Hospital pharmacy” This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.
8 citations
,
April 2015 in “Advances in Psychosomatic Medicine” This review discusses the complex relationship between psychotropic medications and the skin, focusing on cutaneous side effects, dermatologic uses, and psychiatric disorders with skin manifestations, but reports no new findings.
March 2005 in “The Nurse Practitioner” This update provides information on new drug approvals but does not offer new clinical research findings.
September 2022 in “Journal of The American Academy of Dermatology” In this study, the rate of hyperkalemia in women taking spironolactone for acne and related issues was low, but frequent monitoring of potassium trends during treatment may be advisable.
20 citations
,
September 1983 in “Archives of dermatology” This study observed that minimal doses of the arotinoid RO 13-6298 successfully treated two cases of severe psoriasis and psoriatic arthritis unresponsive to traditional therapies, despite some side effects.
19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” This study found that both topiramate and divalproex sodium were similarly effective in reducing headache frequency by over 50% among episodic migraine patients after three months of treatment.
21 citations
,
March 2002 in “Neurology” This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.
October 2025 in “Reactions Weekly”
June 2021 in “Psychiatria Danubina” The antidepressant escitalopram likely caused hair loss in a patient.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This report shares the authors' experience using spironolactone for treating acne in a PCOS clinic, but provides no new clinical results.
1 citations
,
April 2017 in “European Psychiatry” This case study describes a patient who developed mild eosinophilia and a skin rash after starting clozapine, which resolved without discontinuing the medication.
13 citations
,
October 2023 in “Pharmaceutics” This study found that an intranasal gel containing risperidone-loaded glycethosomes significantly enhanced drug bioavailability and improved neuroprotective, antioxidant, and anti-inflammatory effects in schizophrenia-induced rats compared to oral therapies, suggesting a promising alternative for schizophrenic patients who struggle with adhering to oral medication.
October 2014 in “Reactions Weekly”
12 citations
,
April 2018 in “Physiology & Behavior” In this study, clozapine reduced suicide-related behaviors in a schizophrenia-like mouse model, but its effects on exploratory behavior were counteracted by the neurosteroid inhibitor finasteride.